Sarepta Therapeutics Provides Regulatory Update on Duchenne Muscular Dystrophy Therapies
Published: 05 Jun 2026
Author: Rohan Patil
Sarepta Therapeutics has shared news regarding its progress with the U.S. Food and Drug Administration for the development of both its Duchenne muscular dystrophy (DMD) therapeutics, AMONDYS 45 and VYONDYS 53. The company anticipates submitting supplemental new drug applications (sNDAs) to the FDA to receive approval for both products.
Advancing Exon-Skipping Therapies for Duchenne Muscular Dystrophy
The Phase 3 trial of AMONDYS 45 and VYONDYS 53 demonstrated these agents to be safe and effective, involving 225 Duchenne muscular dystrophy patients who were suitable for either exon 45 skipping or exon 53 skipping.
In the rare disease arena, where the disease trajectory may be very different and can take a long time to manifest itself, and often not within the framework of clinical trials, the inclusion of real-world data in addition to clinical trial data is particularly important," said Louise Rodino-Klapac, president, Research & Development and Technical Operations for Sarepta Therapeutics, speaking to the audience.
According to Precedence Research, the Duchenne Muscular Dystrophy Therapeutics Market size was calculated at USD 6.80 billion in 2025 and is predicted to increase from USD 7.80 billion in 2026 to approximately USD 26.88 billion by 2035, expanding at a CAGR of 14.80% from 2026 to 2035, due to increasing demand for advanced genetic therapies and innovative rare disease management solutions.
Industry Impact and Market Outlook
Precision genetic medicine and rare disease innovation are moving towards a more focused direction as biotechnology firms rapidly become the Duchenne muscular dystrophy therapeutics market, with further progress in the development of exon-skipping therapies reflecting this developing trend. Industry-wide, flexibility in regulatory approaches has been taken up by the FDA to include both confirmatory trial data and long-term real-world evidence, which is a positive movement for rare disease therapeutics.
The experiences Sarepta has had on the road to approval of AMONDYS 45 and VYONDYS 53 demonstrate the application of real-world evidence and precision medicine by pharmaceutical and biotechnology companies to meet the unmet medical needs of rare diseases.